# Vafseo® (vadadustat) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vadadustat

> The FDA approved Vafseo® (vadadustat), sponsored by Akebia Therapeutics, Inc. (AKBA), on March 31, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Vafseo® (vadadustat) FDA approved?

Yes. The FDA approved Vafseo® (vadadustat), sponsored by Akebia Therapeutics, Inc. (AKBA), on March 31, 2025. SEC Form 10-Q: "The Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, after the Company received FDA approval for Vafseo, or the BlackRock Maturity Date." [Calendar and source filings](https://sec-api.dev/pdufa/vadadustat)

Source: SEC Form 10-Q, accession 0001517022-26-000084, https://www.sec.gov/Archives/edgar/data/1517022/000151702226000084/akba-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/pdufa/vadadustat#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Vafseo® (vadadustat) |
| Codes | AKB-6548 |
| Sponsor | Akebia Therapeutics, Inc. (AKBA) https://sec-api.dev/companies/akba/catalysts |
| Indications | anemia due to ckd in adults, anemia associated with chronic kidney disease, or ckd, anemia due to ckd, anemia due to chronic kidney disease in adults, anemia due to ckd in dialysis, To treat anemia due to chronic kidney disease, [Anemia of Chronic Kidney Disease](https://sec-api.dev/indications/anemia-of-chronic-kidney-disease) |
| Modality | small_molecule |
| FDA designations | none disclosed |

## Timeline

### Mar 2022: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-03-13, last confirmed 2025-11-10.
- SEC Form 10-Q (accession 0001517022-25-000046): "For example, we initially submitted a NDA to the FDA for vadadustat in March 2021 and in March 2022 the FDA issued a CRL to our NDA." https://www.sec.gov/Archives/edgar/data/1517022/000151702225000046/akba-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-038600): "For example, we initially submitted a NDA to the FDA for vadadustat in March 2021 and in March 2022 the FDA issued a CRL to our NDA." https://www.sec.gov/Archives/edgar/data/1517022/000162828025038600/akba-20250630.htm
- SEC Form 10-K (accession 0001628280-25-012470): "We initially submitted a New Drug Application, or NDA, to the FDA for vadadustat in March 2021 and in March 2022, the FDA issued a complete response letter, or CRL, to our NDA." https://www.sec.gov/Archives/edgar/data/1517022/000162828025012470/akba-20241231.htm

### March 29, 2022: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: anemia associated with chronic kidney disease, or CKD.
- First seen 2025-03-13, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22215192_2024_Orig1s000OtherActionLtrs.pdf%22
- SEC Form 10-Q (accession 0001517022-25-000046): "In March 2022, we received a complete response letter, or CRL, from the United States, or U.S., Food and Drug Administration, or FDA, regarding our new drug application, or NDA, for vadadustat for the treatment of anemia associated with chronic kidney disease, or CKD." https://www.sec.gov/Archives/edgar/data/1517022/000151702225000046/akba-20250930.htm
- SEC Form 10-Q (accession 0001517022-25-000046): "For example, in March 2022, we received the CRL for Vafseo indicating that the FDA had determined that it could not approve the NDA in its present form, thus delaying any potential approval of Vafseo." https://www.sec.gov/Archives/edgar/data/1517022/000151702225000046/akba-20250930.htm
- SEC Form 10-Q (accession 0001517022-25-000046): "For example, in March 2022, we received the CRL from the FDA for our NDA for Vafseo in which the FDA concluded that the data in the NDA did not support a favorable benefit-risk assessment of Vafseo for dialysis and non-dialysis patients." https://www.sec.gov/Archives/edgar/data/1517022/000151702225000046/akba-20250930.htm
- SEC Form 10-Q (accession 0001517022-25-000046): "In March 2022, we received the CRL from the FDA regarding our NDA for vadadustat for the treatment of anemia due to CKD." https://www.sec.gov/Archives/edgar/data/1517022/000151702225000046/akba-20250930.htm
- SEC Form 10-Q (accession 0001517022-25-000046): "For example, we initially submitted a NDA to the FDA for vadadustat in March 2021 and in March 2022 the FDA issued a CRL to our NDA." https://www.sec.gov/Archives/edgar/data/1517022/000151702225000046/akba-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-038600): "In March 2022, we received a complete response letter, or CRL, from the United States, or U.S., Food and Drug Administration, or FDA, regarding our new drug application, or NDA, for vadadustat for the treatment of anemia associated with chronic kidney disease, or CKD." https://www.sec.gov/Archives/edgar/data/1517022/000162828025038600/akba-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-038600): "For example, in March 2022, we received the CRL for Vafseo indicating that the FDA had determined that it could not approve the NDA in its present form, thus delaying any potential approval of Vafseo." https://www.sec.gov/Archives/edgar/data/1517022/000162828025038600/akba-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-038600): "For example, in March 2022, we received the CRL from the FDA for our NDA for Vafseo in which the FDA concluded that the data in the NDA did not support a favorable benefit-risk assessment of Vafseo for dialysis and non-dialysis patients." https://www.sec.gov/Archives/edgar/data/1517022/000162828025038600/akba-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-038600): "In March 2022, we received the CRL from the FDA regarding our NDA for vadadustat for the treatment of anemia due to CKD." https://www.sec.gov/Archives/edgar/data/1517022/000162828025038600/akba-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-038600): "For example, we initially submitted a NDA to the FDA for vadadustat in March 2021 and in March 2022 the FDA issued a CRL to our NDA." https://www.sec.gov/Archives/edgar/data/1517022/000162828025038600/akba-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-023460): "In March 2022, we received a complete response letter, or CRL, from the United States, or U.S., Food and Drug Administration, or FDA, regarding our new drug application, or NDA, for vadadustat for the treatment of anemia associated with chronic kidney disease, or CKD." https://www.sec.gov/Archives/edgar/data/1517022/000162828025023460/akba-20250331.htm

### March 27, 2024: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2025-03-13, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001517022-26-000084): "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000084/akba-20260930.htm
- SEC Form 10-Q (accession 0001517022-26-000051): "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm
- SEC Form 10-Q (accession 0001517022-26-000039): "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000039/akba-20260331.htm
- SEC Form 10-K (accession 0001517022-26-000020): "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/akba-20251231.htm
- SEC Form 10-Q (accession 0001517022-25-000046): "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000151702225000046/akba-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-038600): "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000162828025038600/akba-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-023460): "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000162828025023460/akba-20250331.htm
- SEC Form 10-K (accession 0001628280-25-012470): "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000162828025012470/akba-20241231.htm

### March 27, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat anemia due to chronic kidney disease.
- First seen 2025-03-13, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Vafseo | vadadustat | 3/27/2024 | To treat anemia due to chronic kidney diseaseDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "NDA215192 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20240327, review_priority STANDARD; sponsor_name AKEBIA; product VAFSEO (VADADUSTAT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215192%22
- Press release filed with the SEC (EX-99) (accession 0001517022-26-000047): "In March 2024, Vafseo was approved by the U.S. Food and Drug Administration for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and it has been available in the U.S. since January 2025." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000047/exh991voicedatapr.htm
- SEC Form 10-Q (accession 0001517022-26-000084): "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000084/akba-20260930.htm
- SEC Form 10-Q (accession 0001517022-26-000084): "On March 27, 2024, the FDA approved our NDA for vadadustat under the trade name Vafseo for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000084/akba-20260930.htm
- SEC Form 10-Q (accession 0001517022-26-000051): "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm
- SEC Form 10-Q (accession 0001517022-26-000051): "On March 27, 2024, the FDA approved our NDA for vadadustat under the trade name Vafseo for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm
- SEC Form 10-Q (accession 0001517022-26-000039): "On March 27, 2024, the FDA approved our NDA for vadadustat under the trade name of Vafseo for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000039/akba-20260331.htm
- SEC Form 10-Q (accession 0001517022-26-000039): "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000039/akba-20260331.htm
- SEC Form 10-Q (accession 0001517022-26-000039): "On March 27, 2024, the FDA approved our NDA for vadadustat under the trade name Vafseo for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000039/akba-20260331.htm
- SEC Form 10-K (accession 0001517022-26-000020): "On March 27, 2024, the FDA approved our NDA for vadadustat under the trade name of Vafseo for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/akba-20251231.htm
- SEC Form 10-K (accession 0001517022-26-000020): "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/akba-20251231.htm

### June 30, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-13, last confirmed 2025-03-13.
- SEC Form 10-K (accession 0001628280-25-012470): "The Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, or the Maturity Date, since we received FDA approval for Vafseo prior to June 30, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000162828025012470/akba-20241231.htm

### March 13, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-03-13, last confirmed 2025-03-13.
- Press release filed with the SEC (EX-99) (accession 0001517022-25-000017): "Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update" https://www.sec.gov/Archives/edgar/data/1517022/000151702225000017/drafpr12312024.htm

### March 31, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-05-08, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001517022-26-000084): "The Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, after the Company received FDA approval for Vafseo, or the BlackRock Maturity Date." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000084/akba-20260930.htm
- SEC Form 10-Q (accession 0001517022-26-000051): "The BlackRock Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, after the Company received FDA approval for Vafseo, or the BlackRock Maturity Date." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm
- SEC Form 10-Q (accession 0001517022-26-000039): "The BlackRock Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, after the Company received FDA approval for Vafseo, or the BlackRock Maturity Date." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000039/akba-20260331.htm
- SEC Form 10-K (accession 0001517022-26-000020): "The BlackRock Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, after the Company received FDA approval for Vafseo, or the BlackRock Maturity Date." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/akba-20251231.htm
- SEC Form 10-Q (accession 0001517022-25-000046): "The BlackRock Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, after the Company received FDA approval for Vafseo, or the BlackRock Maturity Date." https://www.sec.gov/Archives/edgar/data/1517022/000151702225000046/akba-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-038600): "The BlackRock Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, after the Company received FDA approval for Vafseo, or the BlackRock Maturity Date." https://www.sec.gov/Archives/edgar/data/1517022/000162828025038600/akba-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-023460): "The BlackRock Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, after the Company received FDA approval for Vafseo, or the BlackRock Maturity Date." https://www.sec.gov/Archives/edgar/data/1517022/000162828025023460/akba-20250331.htm
- SEC Form 10-Q (accession 0001628280-25-023460): "The Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, or the Maturity Date, because we received FDA approval for Vafseo prior to June 30, 2024." https://www.sec.gov/Archives/edgar/data/1517022/000162828025023460/akba-20250331.htm

### late 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-03-13, last confirmed 2025-08-07.
- SEC Form 10-Q (accession 0001628280-25-023460): "For example, we plan to start a Phase 3 trial in the second half of 2025 to potentially expand Vafseo label to include the treatment of late-stage NDD-CKD patients; however, the FDA may not agree with our study design or we may not successfully demonstrate safety and/or efficacy needed to obtain regulatory approval or we may be unable to successfully complete the trial when anticipated, or at all." https://www.sec.gov/Archives/edgar/data/1517022/000162828025023460/akba-20250331.htm
- SEC Form 10-Q (accession 0001628280-25-023460): "For example, we plan to start a Phase 3 trial in the second half of 2025 to potentially expand the Vafseo label to include the treatment of late-stage NDD-CKD patients, however, we may not successfully demonstrate safety and/or efficacy needed to obtain regulatory approval or we may be unable to complete the trial when anticipated or at all." https://www.sec.gov/Archives/edgar/data/1517022/000162828025023460/akba-20250331.htm
- SEC Form 10-K (accession 0001628280-25-012470): "For example, we plan to start a Phase 3 trial in the second half of 2025 to potentially expand Vafseo label to include the treatment of late-stage NDD-CKD patients; however, the FDA may not agree with our study design or we may not successfully demonstrate safety and/or efficacy needed to obtain regulatory approval or we may be unable to successfully complete the trial when anticipated, or at all." https://www.sec.gov/Archives/edgar/data/1517022/000162828025012470/akba-20241231.htm
- SEC Form 10-K (accession 0001628280-25-012470): "For example, we plan to start a Phase 3 trial in the second half of 2025 to potentially expand the Vafseo label to include the treatment of late-stage NDD-CKD patients, however, we may not successfully demonstrate safety and/or efficacy needed to obtain regulatory approval or we may be unable to complete the trial when anticipated or at all." https://www.sec.gov/Archives/edgar/data/1517022/000162828025012470/akba-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001517022-25-000034): "•Akebia is working towards its goal to initiate VALOR, a Phase 3 clinical trial to study the use of vadadustat for treating anemia in late-stage CKD patients who are not on dialysis by the end of this year." https://www.sec.gov/Archives/edgar/data/1517022/000151702225000034/q22025pr.htm

### August 12, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Anemia of Chronic Kidney Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06901505 (To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Akebia Therapeutics." https://clinicaltrials.gov/study/NCT06901505

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Anemia of Chronic Kidney Disease.
- First seen 2026-02-26, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0001517022-26-000019): "•In July, enrolled the first patient in VOCAL, a Phase IIIb trial evaluating three times weekly (TIW) dosing of Vafseo versus ESAs, which is expected to report topline data in Q4 2026." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000019/drafpr12312025.htm
- ClinicalTrials.gov: "NCT06901505 (To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Akebia Therapeutics." https://clinicaltrials.gov/study/NCT06901505
- SEC Form 10-K (accession 0001517022-26-000020): "353 patients have been enrolled, and top-line data from the VOCAL trial is expected in late 2026." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/akba-20251231.htm

### early 2027: topline data readout

- Status: scheduled. Date confidence: half. Indication: anemia due to CKD in dialysis.
- First seen 2026-01-12, last confirmed 2026-01-12.
- Press release filed with the SEC (EX-99) (accession 0001517022-26-000003): "VOICE topline results are expected in early 2027 with the potential to help establish Vafseo as a standard of care to treat anemia due to CKD in dialysis." https://www.sec.gov/Archives/edgar/data/1517022/000151702226000003/akba_2026corporatereleasex.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vadadustat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vafseo® (vadadustat) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vadadustat

```bibtex
@misc{secapidev_pdufa_vadadustat_20261116,
  title        = {Vafseo® (vadadustat) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vadadustat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vadadustat_20261116","title":"Vafseo® (vadadustat) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vadadustat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
